Background As association between systemic inflammation and disease progression has
been suggested, early changes in neutrophil-to-lymphocyte ratio (NLR) and derived NLR …

Objectives Derived neutrophil-to-lymphocytes ratio (dNLR) has recently been reported as a
novel potential biomarker associated with prognosis of non-small cell lung cancer (NSCLC) …

Background: Recent studies have demonstrated the predictive value of pretreatment
neutrophil-to-lymphocyte ratio (NLR) in advanced cancers; however, the role of NLR in …

Background: Baseline dNLR is associated with ICI outcomes in advanced NSCLC; we
previously reported that the early dNLR change during ICI was correlated to benefit in 292 …

Background High neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) are
associated with poor prognosis in cancer patients treated with Immune checkpoint inhibitors …

Background: Immunotherapy with programmed death receptor-1 (PD-1) antibodies has
changed the paradigm of advanced NSCLC treatment. These checkpoint inhibitors showed …

Background Neutrophil-to-lymphocyte ratio (NLR) has recently attracted attention as a
prognostic predictor in patients with non-small cell lung cancer (NSCLC) who receive …

2596 Background: ICIs have revolutionized the therapeutic landscape of NSCLC. However,
with the exception of PD-L1 expression, predictive biomarkers are lacking. The aim of this …

Purpose The aim of this study was to identify the prognostic value of blood neutrophil–
lymphocyte ratio (NLR) in patients with advanced non-small-cell lung cancer (NSCLC) who …

Purpose Pseudo-progression (PsPD) is a rare phenomenon observed in< 5% of cases of
non-small cell lung cancer (NSCLC). This event is challenging for both clinicians and …